Eurofins CDMO Alphora expands its service footprint for monoclonal antibodies, therapeutic proteins, and antibody drug conjugate manufacturing
Sidra Satti, Marketing Specialist, Eurofins CDMO Alphora, sidra.satti@bpt.eurofinsca.com
Post pandemic, due to a rising number of monoclonal antibody (mAbs) based entrants to the market, research and development in this sector has become an increasing focus. With pandemic readiness also being a top priority to minimise supply chain disruptions, life sciences companies look to solutions for chronic diseases, in particular cancer, where cellular specificity is paramount. mAbs are a highly targeted solution that addresses this gap.
Eurofins CDMO Alphora continues to strive to provide solutions for life-saving therapies. To build upon our more than 20 years of experience in small molecule and high potent API, Eurofins CDMO Alphora is expanding its mAbs, therapeutic proteins, and ADCs manufacturing footprint. Its new 50,000 ft2 GMP biologics manufacturing facility in Mississauga, Ontario, to be operational by April 2026, will be dedicated to clinical and commercial applications to bolster biomanufacturing capabilities and preparedness for future
pandemics.
The new facility builds upon existing Development & Pilot Scale up facilities with capabilities spanning analytical services, upstream & downstream development, process design & scale up, and bioassays.
With extensive expertise in High Potent APIs, Eurofins CDMO Alphora is uniquely positioned to provide both small and large molecule services “under one roof”.
For more information: www.eurofins.com/biopharma-services/cdmo/news-events/press-releases/ or Contact Us